Managing Cardiometabolic Risk: Practical Considerations and Emerging Approaches 2018

Chicago, IL US

Click "Start" to evaluate sessions, claim CME & Maintenance of Certification (MOC) points, and print a certificate of attendance or certificate of participation

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

  1. Provide your board-certification information in your educational profile
  2. Evaluate the MOC sessions you attended through this form

Update Profile

Target Audience

This program should be of substantial interest to: endocrinologists and endocrine fellows, pediatric endocrinologists and pediatric endocrine fellows, endocrine physician’s assistants and internal medicine physicians who treat diabetes, geriatricians, nurses, and other healthcare professionals who treat patients with diabetes.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

  • Incorporate standards of care when evaluating and managing cardiometabolic risk factors in diabetes, obesity, and dyslipidemia
  • Apply individualized treatment strategies in diabetes management, taking newly available therapies and technologies into consideration
  • Facilitate lifestyle modification, utilize pharmacotherapy, and monitor non-pharmaceutical option outcomes in patients with obesity
  • Recognize and treat genetic and acquired forms of dyslipidemia taking comorbid conditions and cardiac imaging into consideration

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
Systems-based Practice
Topic Area: 
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Health Disparities
Nutrition
Obesity
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 8.00 ABIM MOC
  • 8.00 AMA PRA Category 1 Credits
  • 8.00 CME Certificate of Participation
Course opens: 
03/16/2018
Course expires: 
12/31/2018
Rating: 
0
McCormick Place West
2301 S Prairie Ave, Chicago
Chicago, IL 60616
United States

Program Chairs

Robert H. Eckel, MD; Univ of Colorado Sch of Med
Samuel Dagogo-Jack, MD; Univ of Tennessee

Presenters

Silvio E. Inzucchi, MD; Yale Sch of Med
Irl B. Hirsch, MD; Univ of Washington Med Ctr
Carol H. Wysham, MD; Rockwood Clin/Univ of Washington Sch of Med
Vivian Fonseca, MD; Tulane Univ Sch of Med
Michael Schwartz, MD; Univ of Washington
Holly Wyatt, MD; Univ of Colorado
Caroline Apovian, MD; Boston Univ
Sangeeta Kashyap, MD; Cleveland Clinic
Steve Nissen MD; Cleveland Clinic
Michael Blaha, MD; Johns Hopkins
Robert H. Eckel, MD; Univ of Colorado Sch of Med

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Robert H. Eckel, MD: Consultant, Merck & Co., Inc., Novo Nordisk Inc., Sanofi‐Aventis US, LLC; Researcher, Ionis Pharmaceuticals, Inc.; Independent Contractor (incl. contracted research), uniQure Inc.

Silvio E. Inzucchi, MD: Ad Hoc Consultant, Merck & Co., Inc., Janssen Pharmaceuticals, Inc.; Clinical Trial Executive Committee Member, AstraZeneca; Clinical Trial Steering Committee Member, Sanofi‐Aventis US, LLC; Data Monitoring Committee Member, Novo Nordisk Inc.; Publishing Committee Member, Boehringer Ingelheim Pharmaceuticals, Inc.

Carol H. Wysham, MD: Consultant/Advisor: Abbott Laboratories, AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly & Co., Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi‐Aventis US. Speaker's Bureau: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly & Co., Insulet Corp., Novo Nordisk Inc., Sanofi‐Aventis US.

Vivian Fonseca, MD: Research Support (to Tulane): Grants from, Asahi, Bayer. Consulting: Takeda, Novo Nordisk, Sanofi- Aventis, Eli Lilly, Astra- Zeneca. Clinical Trial Leadership/ DSMB/ Committees- Takeda, Novo Nordisk, Sanofi- Aventis, Asahi. •Microbiome Technologies, BRAVO4Health, Insulin Algorithms

Caroline Apovian, MD; Advisory Board: Amylin Pharmaceuticals, Inc.; EnteroMedics, Inc.; Gelesis; Novo Nordisk Inc.; Nutrisystem; Orexigen Therapeutics, Inc.; Scientific Intake; Zafgen. Contracted Research: Aspire Bariatrics; GI Dynamics; Gelesis; MetaProteomics, LLC; MYOS Corporation; Orexigen Therapeutics, Inc.; Takeda Pharmaceutical Company. Ownership Interest; Science Smart, LLC
​​​​​​ 
The following faculty reported no relevant financial relationships: Irl B. Hirsch, MD; Michael Schwartz, MD

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 8.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Available Credit

  • 8.00 ABIM MOC
  • 8.00 AMA PRA Category 1 Credits
  • 8.00 CME Certificate of Participation

Accreditation Period

Course opens: 
03/16/2018
Course expires: 
12/31/2018